CA3190663A1 - Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders - Google Patents

Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders

Info

Publication number
CA3190663A1
CA3190663A1 CA3190663A CA3190663A CA3190663A1 CA 3190663 A1 CA3190663 A1 CA 3190663A1 CA 3190663 A CA3190663 A CA 3190663A CA 3190663 A CA3190663 A CA 3190663A CA 3190663 A1 CA3190663 A1 CA 3190663A1
Authority
CA
Canada
Prior art keywords
week
dose
patients
weeks
vegf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3190663A
Other languages
English (en)
French (fr)
Inventor
Robert L. Vitti
Alyson J. BERLINER
Karen Chu
Friedrich Asmus
Sergio Casimiro DA SILVA LEAL
Thomas Eissing
Kay D. Rittenhouse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Regeneron Pharmaceuticals Inc
Original Assignee
Bayer Healthcare LLC
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare LLC, Regeneron Pharmaceuticals Inc filed Critical Bayer Healthcare LLC
Publication of CA3190663A1 publication Critical patent/CA3190663A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CA3190663A 2021-05-17 2022-05-16 Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders Pending CA3190663A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163189541P 2021-05-17 2021-05-17
US63/189,541 2021-05-17
US202163235398P 2021-08-20 2021-08-20
US63/235,398 2021-08-20
US202263297420P 2022-01-07 2022-01-07
US63/297,420 2022-01-07
US202263306315P 2022-02-03 2022-02-03
US63/306,315 2022-02-03
PCT/US2022/029462 WO2022245739A1 (en) 2021-05-17 2022-05-16 Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders

Publications (1)

Publication Number Publication Date
CA3190663A1 true CA3190663A1 (en) 2022-11-24

Family

ID=81975181

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3190663A Pending CA3190663A1 (en) 2021-05-17 2022-05-16 Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders

Country Status (23)

Country Link
US (1) US20230302085A1 (https=)
EP (2) EP4647125A3 (https=)
JP (1) JP2024519629A (https=)
KR (1) KR20240008821A (https=)
AU (2) AU2022275786C1 (https=)
BR (1) BR112023023002A2 (https=)
CA (1) CA3190663A1 (https=)
CL (3) CL2023003396A1 (https=)
DK (1) DK4185318T3 (https=)
ES (1) ES3041647T3 (https=)
FI (1) FI4185318T3 (https=)
HR (1) HRP20251282T8 (https=)
IL (1) IL308505A (https=)
JO (1) JOP20230283A1 (https=)
LT (1) LT4185318T (https=)
MX (1) MX2023013554A (https=)
PE (1) PE20240922A1 (https=)
PL (1) PL4185318T3 (https=)
PT (1) PT4185318T (https=)
RS (1) RS67369B1 (https=)
SI (1) SI4185318T1 (https=)
TW (1) TW202313095A (https=)
WO (1) WO2022245739A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4364724T3 (da) 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
IL315347A (en) * 2022-03-15 2024-11-01 Regeneron Pharma Prolonged high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders
IL315374A (en) * 2022-03-15 2024-11-01 Regeneron Pharma Prolonged high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN121712520A (zh) * 2023-06-23 2026-03-20 瑞泽恩制药公司 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案
US20260055171A1 (en) 2024-06-11 2026-02-26 Regeneron Pharmaceuticals, Inc. Vegf antagonists and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
EP1767546B1 (en) 2004-06-08 2012-03-07 Chengdu Kanghong Biotechnologies Co., Ltd. Angiogenesis-inhibiting chimeric protein and the use
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
KR20190049934A (ko) * 2011-01-13 2019-05-09 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
AU2012212047A1 (en) * 2011-02-03 2013-08-22 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
TWI806150B (zh) * 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
CA3010862A1 (en) * 2016-01-08 2017-07-13 Clearside Biomedical, Inc. Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics
HUE059827T2 (hu) * 2017-11-30 2023-01-28 Regeneron Pharma VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére
CN117138171A (zh) 2017-12-13 2023-12-01 里珍纳龙药品有限公司 用于精确剂量输送的装置和方法
DK4364724T3 (da) * 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
US20220306732A1 (en) * 2019-09-12 2022-09-29 Lupin Limited Modified dosing of vegf inhibitors for ophthalmic use

Also Published As

Publication number Publication date
KR20240008821A (ko) 2024-01-19
BR112023023002A2 (pt) 2024-01-23
FI4185318T3 (fi) 2025-10-13
AU2022275786A8 (en) 2023-04-20
AU2022275786B2 (en) 2025-06-05
EP4185318B1 (en) 2025-09-03
JOP20230283A1 (ar) 2023-11-06
HRP20251282T8 (hr) 2025-12-19
MX2023013554A (es) 2023-11-29
PT4185318T (pt) 2025-09-29
CL2025001269A1 (es) 2025-08-22
EP4647125A3 (en) 2026-01-28
EP4185318A1 (en) 2023-05-31
PE20240922A1 (es) 2024-04-30
PL4185318T3 (pl) 2026-01-12
WO2022245739A1 (en) 2022-11-24
LT4185318T (lt) 2025-11-10
DK4185318T3 (da) 2025-09-29
SI4185318T1 (sl) 2025-10-30
HRP20251282T1 (hr) 2025-12-05
IL308505A (en) 2024-01-01
EP4647125A2 (en) 2025-11-12
JP2024519629A (ja) 2024-05-21
RS67369B1 (sr) 2025-11-28
AU2022275786C1 (en) 2025-12-11
CL2023003396A1 (es) 2024-06-07
ES3041647T3 (en) 2025-11-13
AU2025226774A1 (en) 2025-09-25
TW202313095A (zh) 2023-04-01
CL2024002972A1 (es) 2025-01-24
US20230302085A1 (en) 2023-09-28
AU2022275786A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
AU2022275786B2 (en) Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders
US10973879B2 (en) Use of a VEGF antagonist to treat angiogenic eye disorders
CN107001457A (zh) 用于治疗血管性眼病的方法和制剂
US20230295266A1 (en) Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
US20240024420A1 (en) Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
HK40094129A (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
HK40094129B (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
US20250025531A1 (en) Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
EA051980B1 (ru) Расширенные схемы применения высоких доз антагониста vegf для лечения ангиогенных нарушений со стороны глаза
HK40099476A (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
HK40119109A (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
CA3190733A1 (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
HK40099475A (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
CA3190726A1 (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231117

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240917

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250117

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250214

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250214

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250214

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED

Effective date: 20250220

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250220

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250221

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250423

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST

Effective date: 20250603

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST

Effective date: 20250603

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250606

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250609

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250609

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250609

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED

Effective date: 20250620

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250620

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250702

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250730

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT

Effective date: 20250730

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250730

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250730

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250730

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251003

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260422

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260422